| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 9 Nov 2025 | 27 Oct 2025 |
| Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2025 inter alia to consider and approve Please find enclosed. Please find enclosed. Board at its Meeting held today, i.e., November 09, 2025 has inter-alia, approved the appointment of Senior Management Personnels of the Company: 1. Mr. Hemant Gundare as a Head Corporate - EHS (Environment, Health & Safety) and Senior Management Personnel of the Company w.e.f November 10, 2025 and 2. Mr. Shrihari S. Mane as a Chief Technology Officer (API) and Senior Management Personnel of the Company w.e.f November 10, 2025. (As Per BSE Announcement Dated on 09.11.2025) | ||
| Board Meeting | 12 Aug 2025 | 1 Aug 2025 |
| Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 inter alia to consider and approve The unaudited financial results (standalone and consolidated) for the quarter ended June 30 2025. Please find enclosed (As Per BSE Announcement Dated on:12.08.2025) | ||
| Board Meeting | 10 May 2025 | 25 Apr 2025 |
| Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2025 inter alia to consider and approve the audited financial results (standalone and consolidated) for the quarter and year ended March 31 2025 and recommendation of dividend if any for the financial year ended March 31 2025. The Audited Financial Results and Statements of the Company (Standalone and Consolidated) for the Quarter and Year ended March 31, 2025, based on the recommendation of the Audit Committee. (As Per BSE Announcement Dated on :10.05.2025) | ||
| Board Meeting | 5 Feb 2025 | 28 Jan 2025 |
| Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2025 inter alia to consider and approve 1. Audited Financial Results of the Company for the quarter and nine-months ended December 31 2024 after these results are reviewed by the Audit Committee of the Board. 2. Declaration of Interim Dividend if any on the equity share capital of the Company for the Financial Year 2024-25. Financial Results For Quarter Ended December 31, 2024 (As per BSE Announcement Dated on 05/02/2025) | ||
| Board Meeting | 13 Dec 2024 | 13 Dec 2024 |
| Appointment of Company Secretary and Compliance officer w.e.f. December 13, 2024 | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.